Find HeartFlow
Find HeartFlow
Professionals
HeartFlow FFR
CT
Analysis
Plaque Analysis
RoadMap Analysis
Preview HeartFlow
PRECISE Trial
Physician Perspectives
Clinical Evidence
Guidelines
Reimbursement
Education
CT-Flow
Patients
Overview
Resources
Billing
About
Our Story
Newsroom
Management Team
Board of Directors
Careers
Contact
Find HeartFlow
Find HeartFlow
Sign In
Web icon
US
Chevron Down icon
US
UK
JP
Newsroom
Press Releases
Chevron Right icon
2023
New HeartFlow RoadMap™ Analysis Now Available in U.S. to Assist CT Readers in Identifying Coronary Artery Narrowings
HeartFlow, Leader in Revolutionizing Precision Heart Care, Closes $215 Million in Series F Funding Led by Bain Capital Life Sciences
Chevron Right icon
2022
Late-breaking Data Demonstrate AHA/ACC Guideline-directed CCTA + FFR
CT
Precision Pathway is Superior to Traditional Testing
HeartFlow Receives FDA 510(k) Clearance for its Plaque Analysis and RoadMap™ Analysis
HeartFlow Announces Late Breakers Presentation at the 2022 American Heart Association (AHA) Scientific Sessions
Presented at SCCT - New Plaque Clinical Data Provides Additional Insights on Anatomy and Physiology in Clinical Decision Making for Patients
HeartFlow Appoints Monica Tellado as CFO
HeartFlow Announces CEO Transition
HeartFlow Announces Mutual Termination of Business Combination Agreement
HeartFlow Appoints Timothy Barabe to its Board of Directors
Chevron Right icon
2021
HeartFlow Files for FDA Clearance of Next Generation Product Offering to Help Evaluate the Presence of Narrowings and Plaque in the Coronary Arteries
HeartFlow Appoints Dr. Wayne J. Riley to its Board of Directors
CMS Sets National Payment Rate for the HeartFlow Analysis in Doctors’ Offices and Imaging Centers
HeartFlow Analysis is First AI-Enabled Technology to be Recognized by the American College of Cardiology and American Heart Association Guidelines as Important Tool in Diagnosing and Treating Heart Disease
HeartFlow Announces Enrollment of First Two Patients in REVEALPLAQUE Trial
HeartFlow Holding, Inc. Provides Selected Preliminary Second Quarter 2021 Financial Results and Updated Guidance for Full Year 2021
HeartFlow Announces Enrollment of First Three Patients in FUSION Trial
HeartFlow to Present at the Morgan Stanley Global Healthcare Conference
HeartFlow Joins The Board Challenge as Newest Pledge Partner
HeartFlow Appoints John Farquhar as Chief Operating Officer
HeartFlow, the Leader in Precision Heart Care, Announces Merger with Longview Acquisition Corp. II to Become a Publicly Traded Company
Late-Breaking Data Confirm the Accuracy of the HeartFlow Planner in Modeling Post-PCI Outcomes
New 10-Year Data Demonstrate Superiority of the HeartFlow Analysis in Predicting Long-Term Outcomes in Patients with Coronary Artery Disease
HeartFlow Announces Completion of Patient Enrollment in the PRECISE Trial
HeartFlow and MedAxiom Announce Collaboration to Improve Care Delivery for Patients with Coronary Artery Disease
NICE Renews Support for Use of AI-powered HeartFlow Analysis in Heart Disease Diagnosis
New Medicare Local Coverage Determinations Published for the HeartFlow Analysis
NHS England and NHS Improvement mandate adoption of AI-powered HeartFlow Analysis to fight coronary heart disease
Chevron Right icon
2020
New JAMA Network Open Publication Demonstrates the Coronary CT-HeartFlow Analysis Pathway is ‘Dominant’ Compared to Stress Testing in Cost-Effectiveness Analysis
HeartFlow Appoints Cybersecurity Expert Julie Cullivan to its Board of Directors
HeartFlow Highlights Two Presentations at the 2020 American Heart Association Virtual Meeting
HeartFlow Applauds Healthcare Stakeholders’ Push for Change in How Coronary Artery Disease is First Diagnosed
New Data Highlight a Significant Increase in Cardiovascular Treatment Efficiency when the HeartFlow Analysis is Incorporated into the Diagnostic Pathway
Chevron Right icon
2019
HeartFlow Announces FDA Clearance for HeartFlow Planner
NHS England to Extend Reimbursement for the HeartFlow Analysis through Innovation and Technology Payment (ITP) Program
Use of HeartFlow Planner Leads to Change in Treatment Strategy in Nearly Half of Patients with Coronary Heart Disease
Late-Breaking Data Reinforces How the HeartFlow Analysis Can Help Physicians Precisely Stratify Heart Disease Patients and Deliver More Personalized Care
Fast Company Names HeartFlow One of the World’s Most Innovative Companies
HeartFlow Survey: Fewer than 1/3 of Americans Know Biggest Health Threat
New JACC Publication Reinforces Value of a Coronary CTA + HeartFlow Analysis- Guided Pathway for Diagnosing Heart Disease
Chevron Right icon
2018
HeartFlow Initiates PRECISE Randomized Clinical Trial
HeartFlow Receives National Reimbursement Approval in Japan
HeartFlow Analysis Enables Physicians to Confidently and Safely Differentiate Patients in Need of Invasive Treatment and Patients Who Can be Managed Medically for Coronary Artery Disease
NHS Hospitals Turn to Deep Learning and Advanced Algorithms to Fight Heart Disease
HeartFlow Announces New Commercial Coverage with UnitedHealthcare, Largest Health Insurer in U.S.
HeartFlow Analysis Demonstrates Highest Diagnostic Performance for Detecting Heart Disease Compared to Other Non-Invasive Tests
NHS England to Provide Innovation and Technology Payment (ITP) to Drive Adoption of HeartFlow Analysis in the United Kingdom
HeartFlow Announces Collaborative Research Agreement with Imperial College London
HeartFlow Enters into Licensing Agreement with Cedars-Sinai for Coronary Plaque Assessment Technology
View archives >>